Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 174, 105829
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81773253)
- Natural Science Foundation of Jiangsu Province (BK20170261)
- Xuzhou Medical University (TD202003)
This publication has 25 references indexed in Scilit:
- Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells–a completed study overviewBiochemical Society Transactions, 2016
- Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinomaThe Lancet Oncology, 2016
- Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with MelanomaClinical Cancer Research, 2015
- Chemokines and Chemokine Receptors: Positioning Cells for Host Defense and ImmunityAnnual Review of Immunology, 2014
- Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast CancerCancer Research, 2014
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsCancer Letters, 2013
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid TumorsClinical Cancer Research, 2011
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- CD4+ T Cells Are Able to Promote Tumor Growth through Inhibition of Tumor-Specific CD8+ T-Cell Responses in Tumor-Bearing HostsCancer Research, 2005